Cargando…
Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
Autores principales: | Swart, Joost, Consolaro, Alessandro, Horneff, Gerd, Hyrich, Kimme L, Bovis, Francesca, Melo-Gomes, Jose, Alexeeva, Ekaterina, Lanni, Stefano, Ganser, Gerd, Panaviene, Violeta, Anton, Jordi, Foeldvari, Ivan, Stanevicha, Valda, Nielsen, Susan, Trauzeddel, Ralf, Ailioaie, Constantin, Quartier, Pierre, Hospach, Toni, Susic, Gordana, Trachana, Maria, Weller-Heinemann, Frank, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184298/ http://dx.doi.org/10.1186/1546-0096-12-S1-P7 |
Ejemplares similares
-
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
por: Swart, Joost, et al.
Publicado: (2018) -
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
por: Giancane, Gabriella, et al.
Publicado: (2020) -
Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2022) -
Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2023) -
Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients
por: Consolaro, Alessandro, et al.
Publicado: (2014)